FIGURE 4.

CC induce coagulation activation dependent on an initial complement activation. Whole blood was incubated with CC (500, 1000, or 2000 μg/ml), PBS/HSA, or E. coli (1 × 10⁷ particles/ml) for 240 min with the C3 inhibitor CP40, the C5 inhibitor eculizumab, or their respective controls (scrambled peptide for CP40 or rituximab as control for eculizumab). (A) PTF1.2 production following C3 inhibition (CP40; n = 7 donors). (B) Monocyte TF expression at 120 min of incubation following C3 inhibition (n = 6 donors). (C) PTF1.2 production following complement C5 inhibition (eculizumab; n = 7 donors). (D) Monocyte TF expression at 120 min of incubation following C5 inhibition (n = 6 donors). (E) PTF1.2 following inhibition of complement receptor C5aR1 with PMX53 after 240 min (n = 5 donors). (F) Monocyte TF expression after 120 min of incubation following inhibition of C5aR1 with PMX53 (n = 5 donors). Data are given as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.